Welichem Announces Changes of Directors

BURNABY, BC, Jan. 2, 2014 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V: WBI), announced today that Ryan B. Zeng has been appointed as a new director of the Company effective immediately.

Mr. Zeng has been serving as a senior manager of T&T Supermarket in Richmond,   British Columbia since 2008.  He has extensive experience and knowledge in computer sciences, company operation and management from various industries including technology and supermarket companies over more than 15 years.  Mr. Zeng obtained his Bachelors Degree in Computer Science from Jilin University (China) in 1998.

The Company also announced today that Mr. James Dai has resigned as a director of the Company effective January 2, 2014.  The Company has valued the contribution of Mr. Dai as a director of the Company and Chair of the Audit Committee over the past year and wishes his success in his future endeavors.

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer. For a more complete business and financial profile of the Company, interested parties are encouraged to visit the Company's website, www.welichem.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

SOURCE Welichem Biotech Inc.



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.